Abstract:Abstract Background The live‐attenuated vaccine Bacillus Calmette‐Guérin (BCG), is widely used for the prevention of tuberculosis, and has myriad non‐specific beneficial effects in T1DM, multiple sclerosis, decreasing all‐cause childhood mortality, etc. Alzheimer’s Disease (AD) is a complex neurological disease. The innate immune system, intimately involved in the early and late phases of AD, may prove an ideal target for mono‐ or multi‐pronged therapy against AD. Data from multiple population health studies find that BCG treatment for bladder cancer is linked with decreased incidence of AD. Preclinical data also supports an AD‐beneficial effect of the vaccine. While mechanisms of some of these non‐specific vaccine effects have been elucidated, the mechanism behind BCG’s putative central nervous system (CNS) benefits is unclear. Here, we conducted a pilot open‐label study of the BCG (Tokyo strain) in the older adults to study CNS beneficial effects, particularly as they pertain to AD. Methods Baseline measures of participants (N = 16) with or without mild cognitive impairment (MCI) included cognitive and neuropsychological testing, phlebotomy, and lumbar puncture (LP), followed by an initial intradermal BCG, with a booster given 1mo later. Neuropsychological testing, phlebotomy and LP were repeated at 3mo, 6mo (no LP), and 12mo. The primary endpoints include 1) the safety of the vaccine in older adults and 2) target engagement. Secondary and exploratory endpoints include 1) functional, immunological, and AD‐related biomarker measures and 2) cognitive and neuropsychological effects. Results Our interim analysis demonstrated an overall improvement in repeatable battery for neuropsychological status (RBANS) total score index (TSI), notably in subsections of delayed recall, and visuospatial and constructional indices. Our results also show robust peripheral target engagement and the induction of trained immunity in the peripheral blood cells. We will further show the effects on various AD‐related biomarkers in plasma and cerebrospinal fluid. Conclusion These findings support that the BCG vaccine is safe in older adults and may improve cognition (enrollment of a placebo control group is underway). A further study including subjects with MCI and AD is ongoing. Our interventional studies with BCG begin to explore whether this strategy of retraining the neuroimmune axis can prevent and/or treat AD.

Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders

Novel Genome Polymorphisms in BCG Vaccine Strains and Impact on Efficacy

BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design

Peripheral and Central Nervous System Immune Effects of Bacillus Calmette‐Guérin (BCG) Vaccination in older adults with and without cognitive impairment

A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19

BCG-induced trained immunity: history, mechanisms and potential applications

Intravenous Bacillus Calmette-Guérin (BCG) Induces a More Potent Airway and Lung Immune Response than Intradermal BCG in Simian Immunodeficiency Virus-infected Macaques

BCG Vaccine-The Road Not Taken

Recombinant BCG to Enhance Its Immunomodulatory Activities

Lessons from Bacillus Calmette-Guérin: Harnessing Trained Immunity for Vaccine Development

BCG immunization-induced KLRG1+ NK cells show memory-like responses to mycobacterial and HIV antigens

The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study

Central Memory CD4+ T Cells Are Responsible for the Recombinant Bacillus Calmette-Guérin ΔureC::hly Vaccine's Superior Protection Against Tuberculosis

BCG Provides Short-Term Protection from Experimental Cerebral Malaria in Mice

BCG as a Case Study for Precision Vaccine Development: Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny

Intravenous BCG induces a more potent airway and lung immune response than intradermal BCG in SIV-infected macaques

Benefits of BCG‐induced metabolic switch from oxidative phosphorylation to aerobic glycolysis in autoimmune and nervous system diseases

Bacillus Calmette-Guérin vaccination induces a trained innate immunity phenotype in adults over 50 years of age: A randomized trial in Guinea-Bissau

Vaccines and Dementia: Part I. Non-Specific Immune Boosting with BCG: History, Ligands, and Receptors

An Autophagy-Inducing and TLR-2 Activating BCG Vaccine Induces a Robust Protection Against Tuberculosis in Mice.

The double-sided effects of Mycobacterium bovis bacillus Calmette-Guérin vaccine on helminthic infections – current data and future prospects